Literature DB >> 21486977

Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.

Elizabeth Tronstein1, Christine Johnston, Meei-Li Huang, Stacy Selke, Amalia Magaret, Terri Warren, Lawrence Corey, Anna Wald.   

Abstract

CONTEXT: Since herpes simplex virus type 2 (HSV-2) antibody tests have become commercially available, an increasing number of persons have learned that they have genital herpes through serologic testing. The course of natural history of HSV-2 in asymptomatic, seropositive persons is uncertain.
OBJECTIVE: To evaluate the virologic and clinical course of HSV genital shedding among individuals with symptomatic and asymptomatic HSV-2 infection. DESIGN, SETTING, AND PARTICIPANTS: Cohort of 498 immunocompetent HSV-2-seropositive persons enrolled in prospective studies of genital HSV shedding at the University of Washington Virology Research Clinic, Seattle, and Westover Heights Clinic, Portland, Oregon, between March 1992 and April 2008. Each participant obtained daily self-collected swabs of genital secretions for at least 30 days. MAIN OUTCOME MEASURE: The rate of viral shedding measured by quantitative real-time fluorescence polymerase chain reaction for HSV DNA from genital swabs.
RESULTS: Herpes simplex virus type 2 was detected on 4753 of 23,683 days (20.1%; 95% confidence interval [CI], 18.3%-22.0%) in 410 persons with symptomatic genital HSV-2 infection compared with 519 of 5070 days (10.2%; 95% CI, 7.7%-13.6%) in 88 persons with asymptomatic infection (P < .001). Subclinical shedding rates were higher in persons with symptomatic infection compared with asymptomatic infection (2708 of 20,735 days [13.1%; 95% CI, 11.5%-14.6%) vs 434 of 4929 days [8.8%; 95% CI, 6.3%-11.5%]) (P < .001). However, the amount of HSV detected during subclinical shedding episodes was similar (median, 4.3 [interquartile range, 3.1-5.6] log(10) copies in the symptomatic infection group vs 4.2 [interquartile range, 2.9-5.5] in the asymptomatic infection group, P = .27). Days with lesions accounted for 2045 of 4753 days (43.0%; 95% CI, 39.8%-46.5%) with genital viral shedding among persons with symptomatic genital HSV-2 infection compared with 85 of 519 days (16.4%; 95% CI, 11.2%-23.9%) among persons with asymptomatic infection (P < .001).
CONCLUSION: Persons with asymptomatic HSV-2 infection shed virus in the genital tract less frequently than persons with symptomatic infection, but much of the difference is attributable to less frequent genital lesions because lesions are accompanied by frequent viral shedding.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21486977      PMCID: PMC3144252          DOI: 10.1001/jama.2011.420

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  33 in total

1.  Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.

Authors:  A Wald; L Corey; R Cone; A Hobson; G Davis; J Zeh
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

2.  Virologic characteristics of subclinical and symptomatic genital herpes infections.

Authors:  A Wald; J Zeh; S Selke; R L Ashley; L Corey
Journal:  N Engl J Med       Date:  1995-09-21       Impact factor: 91.245

3.  Recurrence rates in genital herpes after symptomatic first-episode infection.

Authors:  J Benedetti; L Corey; R Ashley
Journal:  Ann Intern Med       Date:  1994-12-01       Impact factor: 25.391

4.  Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir.

Authors:  A Wald; J Zeh; G Barnum; L G Davis; L Corey
Journal:  Ann Intern Med       Date:  1996-01-01       Impact factor: 25.391

5.  Risk factors for the sexual transmission of genital herpes.

Authors:  G J Mertz; J Benedetti; R Ashley; S A Selke; L Corey
Journal:  Ann Intern Med       Date:  1992-02-01       Impact factor: 25.391

6.  Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

Authors:  Lawrence Corey; Anna Wald; Raj Patel; Stephen L Sacks; Stephen K Tyring; Terri Warren; John M Douglas; Jorma Paavonen; R Ashley Morrow; Karl R Beutner; Leonid S Stratchounsky; Gregory Mertz; Oliver N Keene; Helen A Watson; Dereck Tait; Mauricio Vargas-Cortes
Journal:  N Engl J Med       Date:  2004-01-01       Impact factor: 91.245

7.  Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera.

Authors:  R L Ashley; J Militoni; F Lee; A Nahmias; L Corey
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

8.  Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women.

Authors:  R W Cone; A C Hobson; Z Brown; R Ashley; S Berry; C Winter; L Corey
Journal:  JAMA       Date:  1994-09-14       Impact factor: 56.272

9.  Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations.

Authors:  F M Cowan; A M Johnson; R Ashley; L Corey; A Mindel
Journal:  BMJ       Date:  1994-11-19

10.  Psychosocial impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment.

Authors:  J Melville; S Sniffen; R Crosby; L Salazar; W Whittington; D Dithmer-Schreck; R DiClemente; A Wald
Journal:  Sex Transm Infect       Date:  2003-08       Impact factor: 3.519

View more
  116 in total

Review 1.  Immune modulation during latent herpesvirus infection.

Authors:  Douglas W White; R Suzanne Beard; Erik S Barton
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  Preventing sexually transmitted infections: back to basics.

Authors:  Anne Rompalo
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

3.  Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Mina Kalantari; Payam Falatoonzadeh; Sookhee Chun; Chang Hyun Lim; Philip L Felgner; D Huw Davies; Lbachir BenMohamed
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

4.  Sexually transmitted infections and HIV: diagnosis and treatment.

Authors:  Kimberly A Workowski
Journal:  Top Antivir Med       Date:  2012 Apr-May

5.  The scarlet H.

Authors:  David W Kimberlin
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

6.  Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Authors:  Sita Awasthi; John W Balliet; Jessica A Flynn; John M Lubinski; Carolyn E Shaw; Daniel J DiStefano; Michael Cai; Martha Brown; Judith F Smith; Rose Kowalski; Ryan Swoyer; Jennifer Galli; Victoria Copeland; Sandra Rios; Robert C Davidson; Maya Salnikova; Susan Kingsley; Janine Bryan; Danilo R Casimiro; Harvey M Friedman
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

7.  A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.

Authors:  Lesia K Dropulic; Makinna C Oestreich; Harlan L Pietz; Kerry J Laing; Sally Hunsberger; Keith Lumbard; Doreen Garabedian; Siu Ping Turk; Aiying Chen; Ronald L Hornung; Chetan Seshadri; Malisa T Smith; Nancy A Hosken; Sanjay Phogat; Lee-Jah Chang; David M Koelle; Kening Wang; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2019-08-09       Impact factor: 5.226

8.  The impact of brief messages on HSV-2 screening uptake among female defendants in a court setting: a randomized controlled trial utilizing prospect theory.

Authors:  Alexis M Roth; Barbara Van Der Pol; J Dennis Fortenberry; Brian Dodge; Michael Reece; David Certo; Gregory D Zimet
Journal:  J Health Commun       Date:  2014-12-12

9.  Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.

Authors:  Christine Johnston; Jia Zhu; Lichen Jing; Kerry J Laing; Christopher M McClurkan; Alexis Klock; Kurt Diem; Lei Jin; Jeffrey Stanaway; Elizabeth Tronstein; William W Kwok; Meei-Li Huang; Stacy Selke; Youyi Fong; Amalia Magaret; David M Koelle; Anna Wald; Lawrence Corey
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

10.  The Effect of Hormonal Contraception and Menstrual Cycle Timing on Genital Herpes Simplex Virus-2 Shedding and Lesions.

Authors:  Elizabeth Micks; Hyunju Son; Amalia Magaret; Stacy Selke; Christine Johnston; Anna Wald
Journal:  Sex Transm Dis       Date:  2019-01       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.